Cas:119546-69-9 N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine manufacturer & supplier

Chemical Name:N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine

CAS.NO:119546-69-9

Synonyms:N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine

Molecular Formula:C₃₆H₂₈N₂

Molecular Weight:488.62092

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine Use and application,N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine technical grade,usp/ep/jp grade.

Related News: Last year, California became the first state in the country to ban toxic chemicals in cosmetics — including a number of PFAS. Maryland did the same this month, but the laws don’t take effect until 2025, the Post reported. N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine manufacturer It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine supplier Looking after their staff: Airlines are under pressure from their staff, who obviously want to protect themselves. N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine vendor It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. N4,N4′-di([1,1′-biphenyl]-4-yl)-[1,1′-biphenyl]-4,4′-diamine factory Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).